Mental health · Phoenix area, AZ
Mental health studies in Phoenix area, AZ
25 recruiting studies have a site in the Phoenix area. This page includes nearby cities such as Scottsdale, Tempe, Mesa, Chandler.
25 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteers
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
Ecotera Health LLC
- Location
- Phoenix, AZ + 50 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Reviva Pharmaceuticals
- Location
- Phoenix, AZ + 16 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Scottsdale, AZ + 34 other US sites
- Eligibility basics
- Ages 55–95
- RecruitingPhase 3
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Cybin IRL Limited
- Location
- Gilbert, AZ + 27 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Draig Therapeutics Ltd
- Location
- Phoenix, AZ + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
ALTO-100 in Bipolar Disorder With Depression (BD-D)
Alto Neuroscience
- Location
- Phoenix, AZ + 38 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Phoenix, AZ + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Phoenix, AZ + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- Phoenix, AZ + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Tonix Pharmaceuticals, Inc.
- Location
- Phoenix, AZ + 25 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals
- Location
- Phoenix, AZ + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Reunion Neuroscience Inc
- Location
- Gilbert, AZ + 26 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Gilbert, AZ + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Transcend Therapeutics
- Location
- Phoenix, AZ + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
52-week Open Label Safety-Tolerability Study
LB Pharmaceuticals Inc.
- Location
- Chandler, AZ + 22 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie
- Location
- Chandler, AZ + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Syndeio Biosciences, Inc
- Location
- Phoenix, AZ + 22 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Bristol-Myers Squibb
- Location
- Gilbert, AZ + 2 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie
- Location
- Phoenix, AZ + 46 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
AbbVie
- Location
- Phoenix, AZ + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Alto Neuroscience
- Location
- Phoenix, AZ + 11 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study of ALTO-300 in MDD
Alto Neuroscience
- Location
- Phoenix, AZ + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 2
Parenting in 2 Worlds Multisite Trial
Arizona State University
- Location
- Phoenix, AZ + 3 other US sites
- Eligibility basics
- Ages 12+
- RecruitingHealthy volunteers
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
Southwest Autism Research & Resource Center
- Location
- Phoenix, AZ + 1 other US site
- Eligibility basics
- Up to age 18
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.